Global

Home/Global

QINLOCK (ripretinib) – aprobado como cuarta línea de tratamiento para GIST

La FDA aprobó QINLOCKTM (ripretinib) para el tratamiento de adultos con tumor avanzado del estroma gastrointestinal (GIST) que han recibido 3 o más tratamientos previos para su GIST.

By |2020-06-17T11:29:18-04:00June 17th, 2020|Drug Treatment, Global, News, Qinlock|

Salud con Datos Produces Unique Analysis of Chilean & Mexican Patient Registries

This study is the result of a collaborative effort between Chile and Mexico, called Salud con Datos that sought to determine GIST prevalence, patients’ clinical characteristics and survival rates. Our report is the largest of its kind in Latin America.

By |2020-05-07T11:33:29-04:00May 7th, 2020|Global, News, Patient Registry|

Increasing Survival without Borders

The Life Raft Group is pleased to announce the official establishment of our Regional Patient Registry, a partnership with Latin America, which will collect medical history and treatment information from more than 600 GIST patients who are represented by Fundación GIST Mexico, Fundación GIST Chile, and Pontificia Universidad Católica de Chile.

By |2019-12-18T14:34:24-05:00December 18th, 2019|Global, News, Newsletter, Patient Registry|